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Abstract
Treatment with empagliflozin, an inhibitor of the sodium/glucose cotransporter 2 (SGLT2), is
associated with slower progression of diabetic kidney disease. In this analysis, we explored
the hypothesis that empagliflozin may have an impact on urinary peptides associated with
chronic kidney disease (CKD). In this post-hoc, exploratory analysis, we investigated urine
samples obtained from 40 patients with uncomplicated type 1 diabetes (T1D) before and
after treatment with empagliflozin for 8 weeks to for significant post-therapy changes in uri-
nary peptides. We further assessed the association of these changes with CKD in an inde-
pendent cohort, and with a previously established urinary proteomic panel, termed CKD273.
107 individual peptides significantly changed after treatment. The majority of the empagliflo-
zin-induced changes were in the direction of “CKD absent” when compare to patients with
CKD and controls. A classifier consisting of these 107 peptides scored significantly different
in controls, in comparison to CKD patients. However, empagliflozin did not impact the
CKD273 classifier. Our data indicate that empagliflozin induces multiple significant changes
in the urinary proteomic markers such as mucin and clusterin. The relationship between
empagliflozin-induced proteomic changes and clinical outcomes merits further investigation.
Introduction
Diabetes-associated vascular diseases, especially chronic kidney disease (CKD) represent a
major burden for developed societies [1]. Today, treatment of CKD in diabetes, also referred
to as diabetic kidney disease, DKD, is typically initiated when first symptoms are evident: per-
sistent microalbuminuria or decreased glomerular filtration rate (GFR). Standard treatment is
reduction of blood pressure by interfering with the rennin/angiotension/aldosterone systems
(RAAS). SGLT2 inhibition may represent an additional renoprotective intervention–beyond
the use of renin angiotensin aldosterone system blockade–for DKD. [2,3].
Multiple recent reports have demonstrated the potential of proteomic biomarkers in kidney
disease, as reviewed in [4]. While individual biomarkers, like e.g. albuminuria, show
PLOS ONE | https://doi.org/10.1371/journal.pone.0186910 October 30, 2017 1 / 12
a1111111111
a1111111111
a1111111111
a1111111111
a1111111111
OPENACCESS
Citation: Cherney D, Perkins BA, Lytvyn Y,
Heerspink H, Rodrı´guez-Ortiz ME, Mischak H
(2017) The effect of sodium/glucose cotransporter
2 (SGLT2) inhibition on the urinary proteome.
PLoS ONE 12(10): e0186910. https://doi.org/
10.1371/journal.pone.0186910
Editor: Paolo Cravedi, Icahn School of Medicine at
Mount Sinai, UNITED STATES
Received: May 31, 2017
Accepted: September 14, 2017
Published: October 30, 2017
Copyright: © 2017 Cherney et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which
permits unrestricted use, distribution, and
reproduction in any medium, provided the original
author and source are credited.
Data Availability Statement: All relevant data are
within the paper and its Supporting Information
files.
Funding: DC has received consulting fees or
speaking honorarium or both from Janssen,
Boehringer Ingelheim-Eli Lilly, AstraZeneca, Merck,
Sanofi, and his institution has received operating
funding from Janssen, Boehringer Ingelheim-Eli
Lilly, AstraZeneca, Merck. HM is the co-founder
and co-owner of Mosaiques Diagnostics. BAP has
received fees for continuing medical education
considerable variability, this variability can be counteracted by employing high-dimensional
classifiers. In such an approach, multiple biomarkers are combined in a predefined model,
reducing and combining the biomarkers into one variable expressing the probability of the
membership in a specific group (e.g. healthy or CKD) [5]. We have previously developed capil-
lary electrophoresis coupled to mass spectrometry (CE-MS) for the routine application in the
assessment of clinically relevant samples, mostly urine [6] and dialysis fluid [7]. The results
demonstrated that analysis of the urinary proteome enables discrimination between patients
with and without CKD [8], as well as prediction of progression of CKD, irrespective of the
underlying disease mechanism [9]. The CE-MS technology is especially well suited to assess
small proteins and peptides, without the requirement of tryptic digestion [10].
The aim of this post-hoc, exploratory analysis was to investigate if treatment with empagli-
flozin impacts the urinary peptidome, with a special emphasis on urinary peptide biomarkers
associated with CKD–specifically the CKD273 biomarker, which is associated with CKD pro-
gression [11]. Such an impact could serve as indicative of a potential benefit of empagliflozin
prior to onset of CKD, and as potential evidence for the use of empagliflozin in the prevention
of DKD onset and progression.
Materials and methods
Patients and sample collection
Samples were collected as described in previous work during clamped euglycemia and hyper-
glycemia in uncomplicated patients with T1D before and after treatment with empagliflozin
(25 mg daily) for 8 weeks [12]. All patients consented to the study, which was approved by the
University of Toronto University Health Network with approval #11–0213. The available clini-
cal and demographic data were presented previously [12].
Urinary proteome analysis and peptide identification
The urine samples were prepared and analyzed using a P/ACE MDQ capillary electrophoresis
system (Beckman Coulter, Fullerton, USA) on line coupled to a MicroTOF MS (Bruker, Bre-
men, Germany) described previously in detail [13]. Accuracy, precision, selectivity, sensitivity,
reproducibility, and stability of the CE-MS method have been previously described [14]. To
normalize for variability in urinary output, a set of 29 internal standard peptides were used for
calibration, as previously described [15]. Relative abundance of all peptides in a sample is
assessed based on the peak area, and normalized to the 29 standard peptides [15]. This proce-
dure has been applied successfully in multiple previous studies, some based on between 1000
and over 10000 individual samples [16,17]. All detected peptides were deposited, matched, and
annotated in a MicrosoftSQL database [9], allowing for further analysis and comparison
between groups. Sequencing of target peptides was performed as described [18], using Dionex
Ultimate 3000 RSLS nano flow system (Dionex, Camberly UK) and a Beckman CE, coupled to
an Orbitrap Velos MS instrument (Thermo Scientific). To assess the distribution of peptides
in the context of CKD, previously generated datasets [8] were employed. The clinical and
demographic data of this cohort are available from the original publication [8].
Combining peptides into a classifier
To generate a peptide pattern indicative of the impact of empogliflazin, the support vector
machine (SVM)-based MosaCluster software [19] was employed. MosaCluster (version 1.7.0)
was developed for discrimination between different patient groups in the high-dimensional
parameter space by using SVM learning. SVM generates high dimensional models, which rely
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on features (biomarkers) displaying statistically significant differences between data from
patients with a specific disease to controls or other diseases. Each feature allegorizes one
dimension in the n-dimensional parameter space [20]. The two classes (here: prior and after
empagliflozin treatment) are separated by an n-1 dimensional separating hyperplane. The
position of a dataset (a sample) in the n-dimensional dataspace is defined by the amplitude of
the features (the peptides used in the classifier). Classification scores provided by this software
give a numerical value quantifying the Euclidean distance of the dataset to the maximal margin
of the separation hyperplane among cases and controls in multidimensional space, as defined
base on the data in the training cohort. A more detailed description has been published
recently [14].
Statistical analysis
After testing for normal distribution, continuous data were compared by Wilcoxon rank-sum
test, as this test has proven to be of superior statistical power in proteomics datasets [5]. A p-
value of<0.05 was considered to be statistically significant. In order to control for the false dis-
covery rate, the p-values were adjusted by the Benjamini and Hochberg method [21].
Results
All available samples were analyzed blinded. All data on the individual samples are available in
S1 Table. To increase statistical power, data from baseline samples collected during clamped
euglycemia and hyperglycemia were combined for the analysis, and the same was done for all
follow-up samples obtained after empagliflozin treatment for 8 weeks. The investigation of the
proteome of these 160 samples enabled identification of 107 peptides that changed signifi-
cantly between the baseline and post-treatment samples (S2 Table). Fig 1 illustrates the distri-
bution of the 107 peptides before and after treatment with empagliflozin.
To obtain information on the potential relevance of these changes in the context of CKD,
the distribution of these peptides in the cohort of patients with CKD and controls that was
used to define CKD273 was investigated. This cohort consisted of 379 healthy controls, and
230 patients with CKD of various etiologies (including 50 patients with diabetic nephropathy)
[8]. Of the 107 peptides affected by empagliflozin, 79 showed a greater than 25% change in
abundance (either increase or decrease) before and after treatment, and between CKD patients
and healthy controls. In the next step we compared the directional change (up- or down-regu-
lation) induced by empagliflozin to the change observed in CKD. The underlying hypothesis
was that a change in the same direction in CKD and as a result of empagliflozin treatment may
indicate a potential negative effect of empagliflozin, (by inducing a similar response than
CKD) and a change in the opposite direction may indicate a potential positive effect (a change
towards “healthy”). In 60 of the 79 peptides the change after empagliflozin treatment was
opposite to the change observed in CKD, indicating a potential beneficial effect. For 19 pep-
tides, the empagliflozin-induced change was similar to the change observed in CKD.
Amino acid sequences were obtained for 46 of the 79 peptides, all listed in Table 1. When
investigating these 46 sequenced peptides only, the significant changes in peptides derived
from clusterin, alpha-1-antitrypsin, keratin type 2, and mucin were in the direction towards
“healthy”, when comparing healthy controls and CKD. The results were less consistent when
investigating the change in collagen fragments induced by empagliflozin: larger collagen frag-
ments generally appeared to be increased upon treatment, while smaller fragments appear to
be decreased, possibly indicating reduction of specific protease activity involved in the process-
ing of collagen.
Empagliflozin impact on the urinary proteome
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Fig 1. Distribution of the 107 peptides found associated with empagliflozin treatment in the cohort investigated. Each peptide is displayed
based on the mass (in kDa, using a logarithmic scale) and migration time (in minutes). The average relative abundance is represented by the peak
intensity. To depict also the lower abundant peptides, the same 107 peptides with abundance magnified 10-fold are shown on the right. Panel A
Empagliflozin impact on the urinary proteome
PLOS ONE | https://doi.org/10.1371/journal.pone.0186910 October 30, 2017 6 / 12
To investigate how the changes in these 107 peptides relate to CKD, we combined all 107
peptides into an SVM-based classifier to receive a composite score, using the data obtained
from all samples investigated in the context of empagliflozin treatment. The classifier was
trained using all 160 samples, and allowed clear differentiation between the two groups
(treated and untreated) in the training set. This classifier was subsequently applied onto the
609 samples that were also employed in the discovery of CKD273 in the past [8] to investigate
if a significant difference in the scoring in the two groups can be detected, which would indi-
cate a potential impact of empagliflozin treatment on CKD (in both directions, either promot-
ing or suppressing its development). In this independent dataset from patients with CKD of
different etiologies and controls, the mean scoring of the CKD cases was -0.835, the mean scor-
ing of the controls was -0.711 (p = 0.0075 for the between-group difference, Fig 2). These data
further support the initial findings, that the changes induced with empagliflozin are directional
pointing away from CKD and towards the healthy controls (of the 107 peptides significantly
changing in abundance after empagliflozin treatment, 60 peptides pointing towards healthy,
19 pointing towards CKD, 28 appear unchanged, as outlined above), indicating a potential
benefit of empagliflozin.
To further assess the effect of empagliflozin, we applied CKD273, a high-dimensional classi-
fier based on 273 urinary peptides that were found significantly changed in CKD [8,22], onto
the 160 datasets obtained in this study. All baseline samples scored negative, indicating absence
of CKD, in line with the clinical findings. As shown in Fig 3, levels of CKD273 increased
within the negative (CKD absent) range during clamped euglycemia, but not during clamped
hyperglycemia. Overall, no consistent impact of the empagliflozin treatment on CKD273
could be observed in this cohort.
Discussion
In this analysis we investigated the impact of empagliflozin treatment on the urine proteome
in type I diabetes patients with preserved kidney function. In several recent studies urinary
proteomic changes were reported as a consequence of therapeutic intervention, both based on
drugs [13,23], but also on diet or lifestyle [24,25]. Our aim was to determine if a) empagliflozin
treatment has an impact on urinary peptides, and b) if such an impact of empagliflozin treat-
ment would be in the direction of CKD (indicating a negative effect) or towards “healthy”
(indicating a positive effect). We have in several recent studies identified collagen type I frag-
ments as being decreased in the urine in the initial phase of onset of CKD [9,11]. Though this
process was not consistently affected by empagliflozin treatment, among the collagen frag-
ments, larger fragments generally showed changes in the same direction observed in CKD,
while the smaller fragments generally showed changes towards healthy. Further, we detected
an increase in a specific clusterin peptide after empagliflozin treatment. Peptides derived from
clusterin were found decreased in CKD [8], indicating that the observed change presented
here represents an improvement with respect to CKD development.
Of special interest is the upregulation of a mucin fragment as a result of empagliflozin treat-
ment. In a recent manuscript we have identified the decrease of mucin fragments in urine as a
major component in the CKD-induced changes [26]. The data presented here indicate that
empagliflozin treatment may reverse these CKD-induced changes. To assess the impact of the
combined changes in urinary peptides observed as a result of empagliflozin treatment, we
shows the distribution of the 107 peptides before treatment, panel B depicts the distribution after treatment. To ease assessment of changes, the
data from patients before and after treatment were superimposed in panel C, peaks were labeled red before EMPA treatment and green after
EMPA treatment, the yellow fraction of the peak indicates the overlap in abundance between before and after treatment.
https://doi.org/10.1371/journal.pone.0186910.g001
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generated a composite classifier integrating all 107 peptides. When applying this classifier onto
an independent cohort of healthy controls and patients with CKD, we detected a significantly
higher scoring in the group of healthy individuals, indicating a positive impact of
empagliflozin.
Empagliflozin is the first compound that to our knowledge demonstrates a rapid and signif-
icant impact on urinary peptides in the context of diabetes and CKD. In our previous investi-
gations, while short term treatment with irbesartan [23] did not show a significant impact on
urine peptides, longer-term treatment for 2 years did show an impact. No overlap exists
between the changes induced by irbesartan and the changes observed here as a result of empa-
gliflozin, suggesting that empagliflozin has a different, direct impact on urinary peptides,
although the mechanisms responsible for these changes are not yet known.
We also investigated the impact of empagliflozin treatment on CKD273, a urinary peptide-
based classifier associated with CKD onset and progression [9,11,17]. All patients in the study
scored negative for CKD. While this observation was in agreement with the clinical
Fig 2. Box-Whisker blots of the scoring representing the proteome changes induced as a result of empagliflozin
treatment. The clear separation of the groups prior and after treatment is evident. However, when applying this classifier to a
cohort of CKD patients and controls, the controls score slightly, yet significantly (p<0.01) higher (indicative of empagliflozin
treatment) than the CKD patients.
https://doi.org/10.1371/journal.pone.0186910.g002
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characteristics, we did expect that at least some patients would present borderline or positive
scoring for CKD. In these patients, we hypothesized to see an impact of empagliflozin treat-
ment on the classification, a change towards “healthy”. However, all samples scored “healthy”
in this primary prevention cohort, and significant improvement of the “healthy” scoring as a
result of empagliflozin treatment was not to be expected. The CKD273 score increased within
the “CKD absent” range during clamped euglycemia, and we were unable to detect an impact
of empagliflozin on CKD273 during clamped hyperglycemic conditions. Since levels of
CKD273 were all in the CKD absent range at all studied time points in this cohort, it is difficult
to draw any conclusions about prognostic implications in patients with baseline CKD.
This exploratory, post-hoc study has limitations: The sample size was small and the treatment
period was only 8 weeks, perhaps not sufficiently long to observe significant changes in CKD273.
The results may not be generalizable to patients with either type 2 diabetes or patients with evi-
dence of renal disease. Whether SGLT2 inhibition impacts on CKD273 in patients with a back-
ground of renal disease is unknown, and will be examined in future work.
In conclusion, empagliflozin has a significant impact on specific urine peptides, and the
proteomic changes induced by empagliflozin suggest a potential nephroprotective effect. How-
ever, this potential nephroprotective effect needs to be investigated and confirmed in dedicated
clinical trials that are designed to assess the impact of empagliflozin in patients with CKD, and
investigate how these proteomic changes correlate with clinical outcomes.
Fig 3. Distribution of the CKD273 scoring in patients before and after treatment with empagliflozin.
https://doi.org/10.1371/journal.pone.0186910.g003
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Supporting information
S1 Table. In this table the normalized relative abundance of all peptides or proteins identi-
fied in this study is listed, for all subjects. Original ID of the samples is given on the top. For
all peptides or proteins, internal Peptide ID, mass and migration is given. In addition,
sequence, original protein, as well as start and stop amino acid position is given, where applica-
ble.
(XLSX)
S2 Table. Listed are the 107 peptides found significantly changes upon empagliflozin treat-
ment. The table lists the mass (in Da) and migration time (CE-T, in minutes), the relative
abundance before (Pre EMPA) and after (Post EMPA) treatment, and the fold-change induced
by empagliflozin (EMPA-ind change). Further, the average abundance in patients with CKD
(CKD mean) and controls (control mean) as well as the fold-change observed in CKD (CKD-
induced) is listed. Where applicable, the Sequence, and protein Name and Symbol are given.
For all peptides, the unadjusted p-value (for the difference prior and after empagliflozin treat-
ment), the AUC, and the Benjamini-Hochberg (BH) adjusted p-value is listed.
(XLSX)
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